The engagement of a specialized partnership advisor and the existence of ready-to-initiate Phase 2 trial materials suggest deal momentum is building. Monitor for partnering announcements over the next 6-12 months as a binary catalyst; the company's micro-cap status means any deal could be transformational.
Price Chart
Executive Summary
Immuron engaged Pullan Consulting to assist in securing a strategic partnership for its IMM-529 (C. difficile infection) program, which has FDA IND approval and is Phase 2-ready with completed drug product and a clinical trial protocol. The filing includes a third-party revenue projection of US$400M in base-case yearly revenue if IMM-529 is positioned at first recurrence, but no partnership agreement or financial transaction has been executed.
Key Facts
- Immuron engaged Pullan Consulting, a life sciences advisory firm, to advance partnering strategy for IMM-529
- IMM-529 has FDA IND approval (IND 32095) for a Phase 2 clinical trial in C. difficile infection
- A Phase 2 trial protocol is completed: randomized, double-blind, placebo-controlled, up to 60 subjects at 3 Australian sites
- Drug product has been manufactured and released for clinical trial supply
- Third-party opportunity assessment by Lumanity projects base-case yearly revenue of US$400M if IMM-529 is positioned at first recurrence
- Preclinical data showed 80% prevention of primary disease (P=0.0052), 67% protection from recurrence (P<0.01), and 78.6% treatment of primary disease (P<0.0001)
- The company is seeking a partner; no deal has been signed yet
Financial Impact
Third-party projection of US$400M base-case yearly revenue if positioned at first recurrence; historical CDI deal comparables show upfront payments of $1-50M, milestones up to $570M, and mid-to-high single-digit royalties
Risk Factors
- No partnership agreement has been signed; partnering process may not result in a deal
- Phase 2 trial has not yet commenced; clinical data is preclinical only
- Revenue projections are third-party estimates, not company guidance
- Micro-cap company ($7M market cap) with no current revenue from IMM-529
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-075233 |
| Document: ea0297074-6k_immuron.htm | 0001213900-26-075233 |
| Document: 0001213900-26-075233-index-headers.html | 0001213900-26-075233 |
| Document: 0001213900-26-075233-index.html | 0001213900-26-075233 |
| Document: 0001213900-26-075233.txt | 0001213900-26-075233 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9300 (+0.00%) |
Oct 23, 2026 4d ago | 6-K | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 23, 2026 4d ago | 424B5 | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 21, 2026 6d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9300 (−2.00%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9300 (−5.30%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9300 (−10.58%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9300 (−25.90%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9300 (−48.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers